Evidence map›Paper›PMID 41591649›Full record

Trial reportAdvances in therapy2026

Efficacy and Safety of Switching to Picankibart from Non-interleukin-23 Subunit p19 Inhibitors in Patients with Plaque Psoriasis: A Multicenter, Open-Label, Phase 2 Trial.

Qing Yang, Bin Yang, Heng Gu, Liming Wu, Lanying Qin, Lihua Wang, Yumei Li, Lixiong Gu, Zhu Shen, Siping Zhang and 15 more

Registry-linked trialAbstract readMulticenter StudyClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05970978 (A Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IBI112 in Participants With Psoriasis Who Were Treated With Biologics and Switched to IBI112), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05970978 phase2completednot on this map

A Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IBI112 in Participants With Psoriasis Who Were Treated With Biologics and Switched to IBI112

TypeinterventionalSponsorInnovent Biologics (Suzhou) Co. Ltd.Ran2023 to 2025Enrolled152ConditionsPsoriasisArmsregular treatment, Intensive treatment
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Qing YangThe Affiliated Dermatology Hospital of Shandong First Medical University, Jinan, China.
Bin YangDermatology Hospital of Southern Medical University, Guangzhou, China.
Heng GuHospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China.
Liming WuHangzhou First People's Hospital, Hangzhou, China.
Lanying QinCangzhou People's Hospital, Cangzhou, China.
Lihua WangJinan Central Hospital, Jinan, China.
Yumei LiAffiliated Hospital of Jiangsu University, Zhenjiang, China.
Lixiong GuAffiliated Hospital of Nantong University, Nantong, China.
Zhu ShenGuangdong Provincial People's Hospital, Guangzhou, China.
Siping ZhangThe First Affiliated Hospital of USTC (Anhui Provincial Hospital), Hefei, China.
Jianyun LuThe Third XiangYa Hospital of Central South University, Changsha, China.
Yuling ShiShanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
Xiaohua TaoZhejiang Provincial People's Hospital, Hangzhou, China.
Yong CuiChina-Japan Friendship Hospital, Beijing, China.
Shifa ZhangGeneral Hospital of Northeast International Hospital, Shenyang, China.
Hong RenThe First People's Hospital of Lianyungang, Lianyungang, China.
Linfeng LiBeijing Friendship Hospital, Capital Medical University, Beijing, China.
Xiaoyong ManThe Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China.
Hui ChenTongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Rong XiaoThe Second XiangYa Hospital of Central South University, Changsha, China.
Ziliang YangThe First Affiliated Hospital of Soochow University, Suzhou, China.
Yuanfang RenInnovent Biologics, Inc., Suzhou, China.
Rouxuan YeInnovent Biologics, Inc., Suzhou, China.
Haiwei DuInnovent Biologics, Inc., Suzhou, China.
Furen ZhangThe Affiliated Dermatology Hospital of Shandong First Medical University, Jinan, China. Zhangfurenlcsy@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe long-term efficacy of biologics in psoriasis is compromised by primary or secondary resistance, and poor treatment adherence due to frequent dosing.

methodsWe assessed the efficacy and safety of switching to an interleukin-23 subunit p19 (IL23p19) inhibitor picankibart at 200 mg every 12 weeks, without a washout period, on skin clearance and quality of life (QoL) in patients with plaque psoriasis.

resultsA total of 152 patients were enrolled, comprising 83 suboptimal responders (static Physician's Global Assessment [sPGA] ≥ 2 or body surface area [BSA] ≥ 3%) and 69 clinical responders (sPGA0/1 and BSA < 3%). More than 96% had received IL-17A inhibitors. Among suboptimal responders, 48.2% achieved sPGA 0/1 and BSA < 3% at week 16 (W16), and the percentage increased to 54.2% at W44. Among responders, 82.6% maintained their therapeutic response at W44. The Dermatology Life Quality Index was reduced by 68.8% in suboptimal responders and by 61.5% in responders from baseline to W44. The most common adverse event was upper respiratory tract infection (25.0%).

conclusionDirectly switching to picankibart resulted in clinically meaningful improvements in both skin lesions and QoL among suboptimal responders. Moreover, the majority of responders maintained their therapeutic response throughout the trial, accompanied by further enhancements in QoL. Picankibart was well tolerated without any new safety signals.

trial registrationClinicalTrials.gov identifier, NCT05970978.

Indexed as

Interleukin-23 Subunit p19PsoriasisAdultAgedDrug SubstitutionFemaleHumansMaleMiddle AgedQuality of LifeTreatment OutcomeInterleukin-23 Subunit p19EfficacyIL23p19PicankibartPlaque psoriasisSafety

Identifiers

PMID41591649

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.